SCHEMBL992229

SCHEMBL992229

O=C(CC1CC1)OCS

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL31426996 0.98 ANPEP (0.36)
SCHEMBL2721040 0.81
SCHEMBL28401685 0.78
SCHEMBL17395272 0.78
SCHEMBL12987123 0.76
SCHEMBL697321 0.76
SCHEMBL14389976 0.76 MGAM (0.44)
SCHEMBL14389978 0.76 MGAM (0.44)
SCHEMBL7782689 0.74 MGAM (0.43)
SCHEMBL18971858 0.74 MGAM (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013028309-A1 TARNISH INHIBITING COMPOSITION FOR METAL LEADFRAMES MACDERMID ACUMEN, INC. (US) 2013-02-28 WO claimed
WO-2007088545-A2 NOVEL PROCESS FOR PREPARING 1-(MERCAPTOMETHYL) CYCLOPROPANEACETIC ACID, A USEFUL INTERMEDIATE IN THE PREPARATION OF MONTELUKAST AND SALTS THEREOF CHEMAGIS LTD. (IL) 2007-08-09 WO claimed
EP-3774733-A1 NOVEL SALT FORMS OF URAT-1 INHIBITORS InventisBio Shanghai Ltd. (CN) 2021-02-17 EP disclosed
WO-2019184897-A1 NOVEL SALT FORMS OF URAT-1 INHIBITORS INVENTISBIO SHANGHAI LTD. (CN) 2019-10-03 WO disclosed
WO-2019183835-A1 NOVEL SALT FORMS OF URAT-1 INHIBITORS INVENTISBIO SHANGHAI LTD. (CN) 2019-10-03 WO disclosed
CN-105541711-B A kind of preparation method of montelukast 齐鲁天和惠世制药有限公司 2018-06-19 CN disclosed
CN-105541710-B A kind of synthetic method of montelukast 齐鲁天和惠世制药有限公司 2018-06-19 CN disclosed
CN-105541786-A Montelukast side chain intermediate and preparing method thereof LUNAN BETTER PHARMACEUTICAL CO LTD 2016-05-04 CN disclosed
WO-2013028309-A1 TARNISH INHIBITING COMPOSITION FOR METAL LEADFRAMES MACDERMID ACUMEN, INC. (US) 2013-02-28 WO disclosed
WO-2011004298-A1 MONTELUKAST HEXAMETHYLENEDIAMINE SALT AND ITS USE FOR THE PREPARATION OF MONTELUKAST SODIUM ALEMBIC LIMITED (IN) 2011-01-13 WO disclosed
WO-2010064257-A1 NOVEL INTERMEDIATES FOR PRODUCING [R-(E)]-1-[[[1-[3-[2-(7- CHLORO -QUINOLINYL)ETHENYL]PHENYL]-3-[2-(1-HYDROXY- METHYLETHYL) PHENYL]PROPYL]THIO] METHYL] CYCLOPROPANEACETIC ACID, MONOSODIUM SALT AND PROCESS THEREOF INNOGENT LABORATORIES PRIVATE LIMITED (IN) 2010-06-10 WO disclosed
WO-2007004237-A2 A PROCESS FOR THE PREPARATION OF MONTELUKAST MATRIX LABORATORIES LTD (IN) 2007-01-11 WO disclosed
EP-1711166-A1 STABLE AMORPHOUS FORMS OF MONTELUKAST SODIUM CHEMAGIS LTD. (IL) 2006-10-18 EP disclosed
EP-1646612-A1 PROCESSES FOR PREPARING MONTELUKAST SODIUM Teva Pharmaceutical Industries Ltd (IL) 2006-04-19 EP disclosed
WO-2006008750-A2 METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES MATRIX LABORATORIES LTD (IN) 2006-01-26 WO disclosed
WO-2006008751-A2 PROCESS FOR THE PREPARATION OF MONTELUKAST AND ITS SALTS MATRIX LABORATORIES LTD (IN) 2006-01-26 WO disclosed
WO-2005105751-A1 PROCESSES FOR PREPARING MONTELUKAST SODIUM TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2005-11-10 WO disclosed
WO-2005074893-A1 STABLE AMORPHOUS FORMS OF MONTELUKAST SODIUM CHEMAGIS LTD. (IL) 2005-08-18 WO disclosed
WO-2003066598-A9 NOVEL ANHYDROUS AMORPHOUS FORMS OF MONTELUKAST SODIUM SALT REDDYS LAB LTD DR (IN) 2003-12-04 WO disclosed
WO-2003066598-A1 NOVEL ANHYDROUS AMORPHOUS FORMS OF MONTELUKAST SODIUM SALT DR. REDDY'S LABORATORIES LTD. (IN) 2003-08-14 WO disclosed